SC
RPRX icon

Savant Capital’s Royalty Pharma RPRX Stock Holding History

Savant Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$840K Buy
16,059
+8,136
+103% +$423K ﹤0.01% 957
2026
Q1 		$380K Buy
7,923
+658
+9% +$28.8K ﹤0.01% 1055
2025
Q4 		$281K Sell
7,265
-150
-2% -$5.72K ﹤0.01% 1090
2025
Q3 		$262K Buy
7,415
+362
+5% +$13.1K ﹤0.01% 1105
2025
Q2 		$254K Buy
+7,053
New +$234K ﹤0.01% 1032

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Savant Capital's RPRX Position: Q2 2026 in Review

Savant Capital increased its Royalty Pharma (RPRX) stake by 103% in Q2 2026, buying an estimated $423K and bringing the position to 16,059 shares worth $840K. The position accounts for ﹤0.01% of the portfolio, ranked #957.

Savant Capital first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Savant Capital held 16,059 shares of Royalty Pharma worth $840K as of Q2 2026.
  • Savant Capital bought 8,136 Royalty Pharma shares in Q2 2026, an estimated $423K.
  • Royalty Pharma made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #957 holding.
  • Savant Capital first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.